Application of an iPSC‐Derived Organoid Model for Localized Scleroderma Therapy
Jie Ma(Beijing Proteome Research Center), Ling Leng(Tianjin University of Traditional Chinese Medicine), Luye Lv(National Defense University), Mansheng Li(Beijing Proteome Research Center), Biyou Li(Anhui Medical University), Wu Zhong(National Institutes for Food and Drug Control), Dunqin Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruiyuan Cao, Shuyang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wěi Li(Shougang (China)), Yujie Wang(Pharmacology Research Institute), Xiao Li(Beijing Proteome Research Center), Jun Li(Anhui University of Traditional Chinese Medicine), Yunping Zhu(Beijing Technology and Business University), Qiyu Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhihong Wu(Academy of Medical Sciences), Junyi Jiang(Beijing Proteome Research Center)
Cited by 36
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
|Science China Life Sciences|2020|2.3k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
Outcome over seven years of healthy adults with and without subjective cognitive impairment
|Alzheimer s & Dementia|2010|582